首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
【24h】

The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

机译:Brucea Javanica油乳液注射液作为晚期非小细胞肺癌的辅助治疗的疗效:META分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose. To evaluate the efficacy of Brucea javanica oil emulsion injection (BJOEI) in patients with advanced non-small-cell lung cancer (NSCLC) during chemotherapy. Method. Electronic database of EMBASE and PubMed and the conference proceeding of ASCO, CNKI, CBMdisc, VIP, and Wanfang database were searched to select RCTs comparing BJOEI plus chemotherapy with chemotherapy alone in the treatment of advanced NSCLC, until June 1,2016. Two reviewers independently performed the analysis according to the inclusion and exclusion criteria. Review Manager 5.3 and STATA 12.0 were employed for data analysis. Result. Twenty-one studies including 2234 cases were included. The pooled result indicated that there were significant differences in ORR (RR = 1.25; 95% CI: 1.14-1.36; P < 0.00001), improvement of QOL (RR = 1.87; 95% CI: 1.63-2.15; P < 0.00001), nausea and vomiting (RR = 0.67; 95% CI: 0.46-0.98; P = 0.04), leukopenia (RR = 0.63; 95% CI: 0.52-0.75; P < 0.00001), but there was no difference in thrombocytopenia (RR = 0.78; 95% CI: 0.49-1.23; P = 0.29). Begg's funnel plot and Egger s test indicated that no publication bias was found. The sensitivity analysis suggested the stability of the pooled result. Conclusion. The addition of BJOEI can enhance efficacy, improve QOL, and decrease incidence of nausea and vomiting and leukopenia for advanced NSCLC patients. However, higher quality RCTs are needed to further confirm this finding.
机译:目的。评价化疗期间高级非小细胞肺癌(NSCLC)患者Braucea Javanica油乳液注射(Bjoei)的疗效。方法。搜索了Embase和PubMed的电子数据库以及ASCO,CNKI,CBMDISC,VIP和WANFANG数据库的会议进行,选择RCTS比较Bjoei Plus化疗与化疗,单独处理高级NSCLC,直到6月1,2016。两位审稿人根据包含和排除标准独立执行分析。审查Manager 5.3和Stata 12.0用于数据分析。结果。包括2234例等二十一项研究。汇总结果表明ORR中存在显着差异(RR = 1.25; 95%CI:1.14-1.36; P <0.00001),改善QOL(RR = 1.87; 95%CI:1.63-2.15; P <0.00001),恶心和呕吐(RR = 0.67; 95%CI:0.46-0.98; P = 0.04),白细胞减少(RR = 0.63; 95%CI:0.52-0.75; P <0.00001),但血小板减少症没有差异(RR = 0.78; 95%CI:0.49-1.23; P = 0.29)。 Begg的漏斗情节和Egger S测试表明没有发现出版物偏差。敏感性分析表明汇总结果的稳定性。结论。 Bjoei的添加可以增强疗效,提高QoL和降低恶心和呕吐和白细胞的发病率,用于高级NSCLC患者。但是,需要更高的RCT来进一步证实这一发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号